Crizotinib Shows Promise for Childhood Cancers - NCI
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer | NEJM
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
Phase III trial of crizotinib versus chemotherapy in previously treated... | Download Scientific Diagram
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial - Journal of Thoracic Oncology
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial - Journal of Thoracic Oncology
Trials Highlight Changing Lung Cancer Treatment Landscape - NCI
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls - ScienceDirect
Crizotinib resistance: implications for therapeutic strategies - Annals of Oncology
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer
Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC) — ALK POSITIVE
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) | Molecular Cancer | Full Text
Ensartinib
First-Line ALK+ mNSCLC Clinical Trial - ALECENSA® (alectinib)
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - Lung Cancer
Alectinib Replaces Crizotinib Drug as Potential Therapy for Advanced Lung Cancer
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Ensartinib Tops Crizotinib in ALK-Positive NSCLC | MedPage Today
Crizotinib produces improved OS and PFS in EML4-ALK lung cancer... | Download Scientific Diagram
Crizotinib - Wikipedia
Clinical trials with crizotinib in ALK+ patients | Download Table
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L) - Lung Cancer
